Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:ETONNASDAQ:JANXNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$63.56-2.6%$64.14$52.50▼$77.00$1.41B0.57311,233 shs321,986 shsETONEton Pharmaceuticals$14.01-1.7%$16.62$3.22▼$21.48$382.15M1.19254,373 shs600,219 shsJANXJanux Therapeutics$23.22+0.5%$25.81$22.48▼$71.71$1.37B2.87860,307 shs1.10 million shsVERAVera Therapeutics$23.00-2.4%$22.70$18.53▼$51.61$1.50B1.19979,273 shs1.37 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-2.59%-5.11%+7.26%-8.36%+0.19%ETONEton Pharmaceuticals-1.68%+3.09%-25.87%+5.66%+312.06%JANXJanux Therapeutics+0.52%-0.56%-2.07%-17.81%-44.34%VERAVera Therapeutics-2.38%+1.86%+20.93%-2.50%-36.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals4.2437 of 5 stars3.51.00.03.32.23.31.3ETONEton Pharmaceuticals2.6518 of 5 stars3.53.00.00.02.11.70.6JANXJanux Therapeutics2.2653 of 5 stars3.51.00.00.01.54.20.0VERAVera Therapeutics3.5429 of 5 stars4.61.00.00.02.94.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1326.06% UpsideETONEton Pharmaceuticals 3.00Buy$29.67111.75% UpsideJANXJanux Therapeutics 3.09Buy$95.25310.21% UpsideVERAVera Therapeutics 3.10Buy$65.00182.61% UpsideCurrent Analyst Ratings BreakdownLatest ETON, ANIP, VERA, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/3/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/2/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $65.006/2/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $85.005/29/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $35.005/16/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $26.005/14/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.005/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/7/2025VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.005/7/2025VERAVera TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.005/5/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.24$7.40 per share8.59$19.11 per share3.33ETONEton Pharmaceuticals$39.01M9.63N/AN/A$0.94 per share14.90JANXJanux Therapeutics$10.59M129.74N/AN/A$19.49 per share1.19VERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.10N/A-3.12%21.35%7.52%8/5/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.18N/A28.02N/A-9.49%-3.15%-1.08%8/4/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.36N/AN/AN/AN/A-9.29%-8.89%8/6/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.00N/AN/AN/AN/A-40.59%-34.54%8/6/2025 (Estimated)Latest ETON, ANIP, VERA, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ETONEton Pharmaceuticals$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025JANXJanux Therapeutics-$0.43-$0.38+$0.05-$0.38$0.59 millionN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98ETONEton Pharmaceuticals1.231.971.43JANXJanux TherapeuticsN/A58.4758.47VERAVera Therapeutics0.1027.6827.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%ETONEton Pharmaceuticals27.86%JANXJanux Therapeutics75.39%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%ETONEton Pharmaceuticals14.89%JANXJanux Therapeutics29.40%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million18.91 millionOptionableETONEton Pharmaceuticals2026.82 million22.83 millionOptionableJANXJanux Therapeutics3059.17 million41.78 millionOptionableVERAVera Therapeutics4063.77 million53.38 millionOptionableETON, ANIP, VERA, and JANX HeadlinesRecent News About These CompaniesVera Therapeutics (NASDAQ:VERA) Shares Gap Up on Insider Buying ActivityJune 28, 2025 | americanbankingnews.comVera Therapeutics director Enright buys shares worth $5.2mJune 27, 2025 | investing.comVor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in FundingJune 27, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Insider Buying ActivityJune 26, 2025 | marketbeat.comInsider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of StockJune 26, 2025 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 SharesJune 25, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Acquires 209,393 SharesJune 25, 2025 | marketbeat.comPolycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsightJune 24, 2025 | theglobeandmail.comBAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsightJune 24, 2025 | finance.yahoo.comAnalysts Set Vera Therapeutics, Inc. (NASDAQ:VERA) PT at $65.00June 23, 2025 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesJune 20, 2025 | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)June 19, 2025 | theglobeandmail.comVera Therapeutics, Inc. (NASDAQ:VERA) Short Interest UpdateJune 18, 2025 | marketbeat.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)...June 12, 2025 | marketbeat.comCantor Fitzgerald Comments on VERA FY2026 EarningsJune 11, 2025 | marketbeat.comQ2 EPS Estimates for Vera Therapeutics Increased by WedbushJune 11, 2025 | marketbeat.comVera Therapeutics Inc.June 10, 2025 | barrons.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 9, 2025 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What HappenedJune 9, 2025 | marketbeat.comOtsuka, Vera stake their claims to IgAN treatmentJune 9, 2025 | pharmaphorum.comPOtsuka's kidney disease therapy trial results heat up battle with rival VeraJune 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom5 Small Cap Stocks With Explosive Upside PotentialBy Ryan Hasson | June 23, 2025View 5 Small Cap Stocks With Explosive Upside PotentialETON, ANIP, VERA, and JANX Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$63.56 -1.69 (-2.59%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$63.75 +0.19 (+0.30%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Eton Pharmaceuticals NASDAQ:ETON$14.01 -0.24 (-1.68%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$14.02 +0.01 (+0.07%) As of 07:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Janux Therapeutics NASDAQ:JANX$23.22 +0.12 (+0.52%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$23.50 +0.28 (+1.21%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Vera Therapeutics NASDAQ:VERA$23.00 -0.56 (-2.38%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$23.38 +0.39 (+1.67%) As of 07:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
